Pharmacological treatment of chronic pain the need for CHANGE

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1231-1245

  Varrassi, G ^a   Muller Schwefe G ^b   Pergolizzi, J ^c   Ornska, A ^d   Morlion, B ^e   Mavrocordatos, P ^f   Margarit, C ^g   Mangas, C ^h   Jaksch, W ⁱ   Huygen, F ^j   Collett, B ^k   Berti, M ^l   Aldington, D ^m   Ahlbeck, K ⁿ  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Schmerz und Palliativzentrum ^*  (Germany)

^c Naples Anesthesia and Pain Associates   (United States)

^d Hospicjum Domowe   (Poland)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Clinique Cecil   (Switzerland)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h Hospital de Santo Andre   (Portugal)

ⁱ WILHELMINEN HOSPITAL   (Austria)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k LEICESTER ROYAL INFIRMARY   (United Kingdom)

^l UNIVERSITY OF PARMA   (Italy)

^m CHURCHILL HOSPITAL   (United Kingdom)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Chronic pain; Communication; Educational tools; Multi mechanistic treatment; Neuropathic pain; Vicious circle

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DULOXETINE; FENTANYL; GABAPENTIN; HYPOCHOLESTEROLEMIC AGENT; MORPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE ANTAGONIST; OXYCODONE; PARACETAMOL; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TAPENTADOL; TILIDINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ANALGESIA; ANAPHYLAXIS; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL PRACTICE; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME; CONSTIPATION; CONVULSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENTEROPATHY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HUMAN; HYPERALGESIA; ILEUS; IMMUNOPATHOLOGY; INFORMATION RETRIEVAL; INSOMNIA; LIVER FUNCTION; LIVER TOXICITY; LOW BACK PAIN; MEDICAL DECISION MAKING; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; NOTE; ORTHOSTATIC HYPERTENSION; PAIN; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; PRURITUS; PSYCHOMOTOR DISORDER; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SENSITIZATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TENSION HEADACHE; TREMOR; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING; XEROSTOMIA;

ANALGESICS; CHRONIC DISEASE; HUMANS; PAIN; PRACTICE GUIDELINES AS TOPIC;

EID: 77951065733     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003689175     Document Type: Note

References (100)

1. Coda BA, Bonica JJ. General considerations of acute pain. In: Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica's Management of Pain, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:222-240
2. New Report Finds Pain Affects Millions of Americans. Atlanta, GA: Centers for Disease Control and Prevention 2006. Available at: http://www.cdc.gov/nchs/ pressroom/06facts/hus06.htm [Last accessed 9 July 2009]
3. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333
4. Blyth FM, March LM, Brnabic AJM, et al. Chronic pain in Australia: a prevalence study. Pain 2001;89:127-134
5. Sjøgren P, Ekholm O, Peuckmann V, et al. Epidemiology of chronic pain in Denmark: an update. Eur J Pain 2009;13:287-292
6. Rustoen T, Wahl AK, Hanestad BR, et al. Prevalence and characteristics of chronic pain in the general Norwegian population. Eur J Pain 2004;8: 555-565
7. World Health Organization. Cancer Pain Relief with a Guide to Opioid Availability, 2nd edn. Geneva: World Health Organization, 1996
8. Dworkin R, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132: 237-251
9. Andersson GB. Epidemiological features of chronic low-back pain. Lancet 1999;354:581-585
10. Pergolizzi J, Bö ger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
11. Pain in the elderly with cancer. Cancer Pain Release, 2000, Volume 13, No.2. Geneva, Switzerland: WHO Pain & Palliative Care Communications Program. Available at: https://whocancerpain.bcg.wisc.edu/index?q=node/34 [Last accessed 20 February 2010]
12. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18:1437-1449
13. Schulte E, Hermann K, Berghö fer A, et al. Referral practices in patients suffering from non-malignant chronic pain. Eur J Pain 2009: published online 30 June 2009, doi:10.1016/j.ejpain.2009.05.015
14. Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviours by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006;22:1859-1865
15. Jacobsen R, Sjøgren P, Møldrup C, et al. Physician-related barriers to cancer pain management with opioid analgesics: a systematic review. J Opioid Manag 2007;3:207-214
16. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32:1-32
17. Becker N, Bondegaard Thomsen A, Olsen AK, et al. Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain 1997;73:393-400
18. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain 2006; 7:892-900 (Pubitemid 44854739)
19. Rodriguez MJ. Survey of therapeutic attitudes towards patients with chronic pain in Spanish Pain Units. Rev Soc Esp Dolor 2006;13:525-532
20. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10: 127-135
21. Dunn KM, Croft PR. Epidemiology and natural history of low back pain. Eura Medicophys 2004;40:9-13
22. Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. Anesth Analg 2004;99:510-520
23. Brescia FJ, Portenoy RK, Ryan M, et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992;10: 149-155
24. Vuorinen E. Pain as an early symptom in cancer. Clin J Pain 1993;9:272-278
25. Portenoy RK, Kornblith AB, Wong G, et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer 1994; 74:907-915
26. Donnelly S, Walsh D. The symptoms of advanced cancer. Semin Oncol; 1995:22:67-72
27. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics. International Association for the Study of Pain. Pain 1999; 82:263-274
28. Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-1920
29. Schmidt CO, Schweikert B, Wenig CM, et al. Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain 2009;13:1030-1035
30. Jost L, Roila F. Management of cancer pain. ESMO clinical recommendations. Ann Oncol 2008;19:ii119-21
31. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-1169
32. Victor TW, Alvarez NA, Gould E. Opioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practice. J Pain 2009;10:1051-1057
33. CHANGE PAIN-Treatment Differences. Results of a Market Research Study. Grü nenthal GmbH, Aachen. Available at http://www.change-pain.com/grt- change-pain-portal/GRT-CHANGE-PAIN-PORTAL-Home/Why-Change/Treatment-Differences/ 86600048.jsp [Last accessed 19 January 2010]
34. Collins JJ, Baase CM, Sharda CE, et al. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 2005;47:547-557
35. McNeil JM, Binette J. Prevalence of disabilities and associated health conditions among adults-United States, 1999. CDC Morb Mortal Wkly Rep 2001;50:120-125
36. Workers' Compensation Report. Kew, Victoria: Journal of Risk and Insurance, 1 November 2004
37. Wening CM, Schmidt CO, Kohlmann T, et al. Costs of back pain in Germany. Eur J Pain 2009;13:280-286
38. Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract 2001;14:211-218
39. Mueller-Schwefe GHH, Ueberall MA. Pain intensity of patients. Abstracts of the 11th World Congress on Pain. Sydney, 2005
40. European Medicines Agency. Opinion of the committee for medicinal products for human use pursuant to article 5(3) of regulation (EC) no 726/2004, for nonselective non steroidal anti-inflammatory drugs (NSAIDs). Available at: http://www.emea.europa.eu/pdfs/human/opiniongen/nsaids.pdf [Last accessed 4 October 2009]
41. Kuehn BM. New pain guideline for older patients: avoid NSAIDs, consider opioids. JAMA 2009;302:19
42. Ueberall MA, Mueller-Schwefe G. Individual treatment targets in chronic pain management. Eur J Pain 2006;10:S184
43. Harris J-D. Management of expected and unexpected opioid-related side effects. Clin J Pain 2008;24:S8-13
44. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med 2009;10:654-662
45. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-380
46. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51
47. Davis MP. What is new in neuropathic pain? Support Care Cancer 2007; 15:363-372
48. Ballantyne JC, Shin N. Efficacy of opioids for chronic pain. A review of the evidence. Clin J Pain 2008;24:469-478
49. Pergolizzi J, Wills LM. Multimodal analgesic therapy. In: Shorten G, Carr DB, Harmon D, et al., eds. Postoperative Pain, an Evidence-based Guide to Practitioners. Philadelphia, PA: Saunders Elsevier, 2006:182-196
50. Drug Interactions Website. Available at: http://medicine.iupui.edu/ flockhart/table.htm [Last accessed 20 June 2009]
51. Wilkinson GR. Drug metabolism and variability among patients in drug response. NEJM 2005;352:2211-2221
52. Holmquist GL. Opioid metabolism and effects of cytochrome P450. Pain Med 2009;10:S20-9
53. Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother 2007; 21:15-25
54. McNichol E. Opioid side effects. International Association for the Study of Pain. Pain: Clinical Updates 2007;15:1-6
55. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med 2009;10:35-42
56. Panchal SJ, Mü ller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. J Clin Pract 2007; 61:1181-1187
57. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-20
58. Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage 2007;33:67-77
59. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004;11:3-9
60. Lö tsch J. Opioid metabolites. J Pain Symptom Manage 2005;29:10-24
61. Kneip C, Terlinden R, Beier H, et al. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metabolism Letters 2008;2:67-75
62. Nguyen JK, Fouts MM, Kotabe SE, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006;4:36-41
63. National Disease Therapeutic Index (NDTI). Available at: www.ndti.org [Last accessed 25 October 2007]
64. Patterns of Medication use in the United States. Boston, MA: Slone Epidemiology Center 2005
65. Coller JK, Christrup L, Somogyi A. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009;65:121-139
66. Moulin DE, Morley-Forster PK, Connolly B, et al. Prospective study of the pharmacologic management of chronic neuropathic non-cancer pain. Eur J Pain 2007;11:S82
67. Hawthorn J, Redmond K. Pain: Causes and Management. Oxford: Blackwell Sciences, 1998
68. Chutkan R, Toubia N. Effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal tract: diagnosis by wireless capsule endoscopy. Gastrointest Endosc Clin N Am 2004;14:67-85
69. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106: 13S-24S
70. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-412
71. North RA, Williams JT. How do opiates inhibit neurotransmitter release? Trends Neurosci 1983;6:337-339
72. Dickenson AH. Mechanisms of the analgesic actions of opiates and opioids. Br Med Bull 1991;47:690-702
73. Fabian R. Der chronische Schmerz. Schriftenreihe der Bayerischen Landesapothekerkammer, 1999
74. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-1534
75. Finnerup NB. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
76. Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2\+ channels. Neuropharmacology 2004;46:743-749
77. Eckhardt K, Ammon S, Hofmann U, et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 2000;91: 185-191
78. Dirks J, Fredensborg BB, Christensen D, et al. A randomized study of the effects of single-dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy. Anesthesiology 2002; 97:560-564
79. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel a2-d (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-150
80. Harbord MG. Significant anticonvulsant side-effects in children and adolescents. J Clin Neurosci 2000;7:213-216
81. Sindrup SH, Otto M, Finnerup NB, et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96:399-409
82. 2 agonists. In: Buschmann H, ed. Analgesics: From Chemistry and Pharmacology to Clinical Application. Weinheim, Germany: Wiley-VCH 2002:265-284
83. Mutschler E, Geisslinger G, Kroemer HK, et al. Arzneimittelwirkungen. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2008
84. Lambert O, Bourin M. SNRIs: mechanism of action and clinical features. Expert Rev Neurother 2002;2:849-858
85. Scott ALE. New classes of antidepressant drugs. Adv Psych Treat 1999; 5:104-111
86. Kehlet H, Dahl JB. The value of 'multimodal' or 'balanced analgesia' in postoperative pain treatment. Anesth Analg 1993;77:1048-1056 (Pubitemid 23319808)
87. Gottschalk A, Schroeder F, Ufer M, et al. Amantadine, a N-methyl-D-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesth Analg 2001;93:192-196
88. Vaughan CW. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br J Pharmacol 1998;123:1479-1481
89. Christie MJ, Connor M, Vaughan CW, et al. Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin Exp Pharmacol Physiol 2000;27:520-523
90. Tzschentke TM, Christoph T, Kö gel B. (-)-(1R,2R)-3-(3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel l-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-276
91. Morlion B. The relevance of neuropathic components in severe chronic pain. CHANGE PAIN News and Reviews, 2009. ISSN 2041-8558
92. Heinricher MM, McGaraughty S, Tortorici V. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 2001;85:280-286
93. Hanna M, O'Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804-813
94. Meissner W, Leyendecker P, Mü ller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2008;13:56-64
95. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxyco-done/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-3512
96. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428-440
97. Paulson DM, Kennedy DT, Donovick R, et al. Alvimopan: an oral, peripherally acting, m-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 2005;6:184-192
98. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-2343
99. Afilalo M, Oh C, Okamoto A, et al. Tapentadol immediate release compared with oxycodone immediate release for the relief of moderate-to-severe pain in patients with end stage joint disease. J Pain 2008;9:32
100. Hale M, Upmalis D, Okamoto A, et al. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009; 5:1095-1104